...
首页> 外文期刊>International Journal of Medical Sciences >The extracts of iAstragalus membranaceus/i overcome tumor immune tolerance by inhibition of tumor programmed cell death protein ligand-1 expression
【24h】

The extracts of iAstragalus membranaceus/i overcome tumor immune tolerance by inhibition of tumor programmed cell death protein ligand-1 expression

机译:Astagalus膜的提取物通过抑制肿瘤编程细胞死亡蛋白配体-1表达来克服肿瘤免疫耐受性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

A polysaccharide isolated from the radix of Astragalus membranaceus, called PG2, used in traditional Chinese medicine, with potential hematopoiesis inducing and immunomodulation activities. PG2 extracted from A. membranaceus has been demonstrated as a novel alternative medicine for cancer patients. Recently, we demonstrated that PG2 enhanced chemotherapy through bystander effect and reduced the expression of indoleamine 2, 3-dioxygenase 1 in tumor cells. Many tumors have been proven to have a high expression of programmed cell death protein ligand-1 (PD-L1), which binds with programmed cell death protein-1(PD-1) in immune cells, thus causing immune tolerance within the tumor microenvironment. With decreased expression of PD-L1, increased immune response can be observed, which might be helpful when developing tumor immunotherapy. The antitumor therapeutic effect mediated by PG2 may associate with an inflammatory immune response at the tumor site. However, the molecular mechanism that by which PG2 inhibits PD-L1 is still incompletely known. The expression of PD-L1 was decreased after tumor cells were treated with PG2. In addition, the cell signaling pathway in tumor cells was evaluated by Western blotting analysis after PG2 treatment. PG2 can downregulate the expression of PD-L1 on the cell surface via the protein kinase B (Akt)/mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase beta-1 (p70S6K) pathway. In conclusion, our results indicate that PG2 inhibits PD-L1 expression and plays a crucial role in immunotherapy, which might be a promising strategy combined with other treatments.? The author(s).
机译:从中药中使用的黄芪膜的膜状膜状膜状物中分离的多糖,具有潜在的血液药物诱导和免疫调节活动。从A膜中提取的PG2已被证明是癌症患者的新型替代药物。最近,我们证明PG2通过旁观者效应增强化疗,并降低了吲哚胺2,3-二氧酶1在肿瘤细胞中的表达。已经证明许多肿瘤具有高表达程序的细胞死亡蛋白质配体-1(PD-L1),其在免疫细胞中与编程的细胞死亡蛋白-1(PD-1)结合,从而导致肿瘤微环境中的免疫耐受性。随着PD-L1的表达降低,可以观察到增加的免疫应答,这在发展肿瘤免疫疗法时可能有所帮助。由PG2介导的抗肿瘤治疗效果可以与肿瘤部位的炎症免疫应答相关。然而,通过其中PG2抑制PD-L1的分子机制仍然不完全不完整。用PG2处理肿瘤细胞后PD-L1的表达降低。此外,通过在PG2处理后蛋白质印迹分析评估肿瘤细胞中的细胞信号传导途径。 PG2可以通过蛋白激酶B(AKT)/哺乳动物靶标在细胞表面上的PD-L1的表达下降到雷帕霉素(MTOR)/核糖体蛋白S6激酶β-1(P70S6K)途径的蛋白激酶B(AKT)/哺乳动物。总之,我们的结果表明,PG2抑制PD-L1表达并在免疫疗法中发挥至关重要的作用,这可能是与其他治疗相结合的有希望的策略。作者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号